TD Cowen Boosts Protagonist Therapeutics (NASDAQ:PTGX) Price Target to $100.00

Protagonist Therapeutics (NASDAQ:PTGX) had its target price lifted by stock analysts at TD Cowen from $90.00 to $100.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. TD Cowen’s target price indicates a potential upside of 15.05% from the company’s current price.

Several other brokerages have also issued reports on PTGX. Truist Financial increased their target price on shares of Protagonist Therapeutics from $88.00 to $110.00 and gave the stock a “buy” rating in a research note on Monday, January 5th. Weiss Ratings cut Protagonist Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, February 17th. Barclays boosted their target price on Protagonist Therapeutics from $108.00 to $113.00 and gave the stock an “overweight” rating in a research note on Thursday. Citizens Jmp increased their price target on shares of Protagonist Therapeutics from $102.00 to $112.00 and gave the company a “market outperform” rating in a research report on Thursday. Finally, Jefferies Financial Group upped their price target on Protagonist Therapeutics from $95.00 to $118.00 and gave the company a “buy” rating in a research report on Monday, February 2nd. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $99.31.

Protagonist Therapeutics Price Performance

PTGX stock traded down $0.18 during midday trading on Thursday, reaching $86.92. 261,479 shares of the stock were exchanged, compared to its average volume of 723,181. The company has a fifty day moving average price of $84.07 and a 200 day moving average price of $76.51. Protagonist Therapeutics has a 52 week low of $35.95 and a 52 week high of $96.54. The stock has a market capitalization of $5.43 billion, a PE ratio of 140.42 and a beta of 2.26.

Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings results on Wednesday, February 25th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.16). The business had revenue of $7.44 million for the quarter, compared to the consensus estimate of $14.92 million. Protagonist Therapeutics had a net margin of 21.94% and a return on equity of 6.86%. As a group, analysts anticipate that Protagonist Therapeutics will post 2.43 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Protagonist Therapeutics news, insider Arturo Md Molina sold 13,151 shares of the business’s stock in a transaction on Friday, January 23rd. The shares were sold at an average price of $82.42, for a total value of $1,083,905.42. Following the completion of the sale, the insider directly owned 84,115 shares of the company’s stock, valued at $6,932,758.30. The trade was a 13.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director William D. Waddill sold 20,000 shares of Protagonist Therapeutics stock in a transaction on Friday, February 6th. The stock was sold at an average price of $83.68, for a total transaction of $1,673,600.00. Following the completion of the transaction, the director directly owned 7,825 shares in the company, valued at approximately $654,796. The trade was a 71.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 203,167 shares of company stock worth $16,889,199 over the last 90 days. Insiders own 4.90% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. American Century Companies Inc. boosted its stake in shares of Protagonist Therapeutics by 18.7% in the 2nd quarter. American Century Companies Inc. now owns 813,995 shares of the company’s stock worth $44,990,000 after buying an additional 128,171 shares during the last quarter. Voya Investment Management LLC boosted its position in Protagonist Therapeutics by 8.9% in the third quarter. Voya Investment Management LLC now owns 305,419 shares of the company’s stock worth $20,289,000 after purchasing an additional 25,065 shares during the last quarter. Segall Bryant & Hamill LLC bought a new stake in shares of Protagonist Therapeutics during the 2nd quarter valued at about $6,641,000. Nan Fung Trinity HK Ltd. bought a new stake in shares of Protagonist Therapeutics during the 2nd quarter valued at about $7,464,000. Finally, Bank of New York Mellon Corp increased its position in shares of Protagonist Therapeutics by 3.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 388,082 shares of the company’s stock valued at $21,449,000 after purchasing an additional 11,219 shares during the last quarter. 98.63% of the stock is owned by hedge funds and other institutional investors.

Protagonist Therapeutics News Roundup

Here are the key news stories impacting Protagonist Therapeutics this week:

• Positive Sentiment: Barclays raised its price target to $113 and maintained an “overweight” rating, implying ~31% upside versus the recent price. Benzinga
• Positive Sentiment: Citizens Jmp raised its target to $112 and gave a “market outperform” rating, signaling analyst confidence in upside (~30% from the recent price). Benzinga
• Positive Sentiment: Corporate update / corrected press release: Protagonist said it submitted an NDA for rusfertide to the FDA (potential approval/launch this year), expects to likely opt out of a 50:50 profit/loss sharing arrangement with Takeda in a Q2 window, expects a U.S. regulatory decision for ICOTYDE (icotrokinra) in 2026, and plans PN-881 Phase 1 completion by mid-2026 while expanding preclinical pipeline — items that materially increase near- and mid-term commercial upside if approvals proceed. Correction / Corporate Update
• Neutral Sentiment: Company posted its formal fourth-quarter and full-year 2025 results and corporate update (full release available). This provides official detail that investors will parse for guidance and cash runway. Press Release
• Negative Sentiment: Q4 results disappointed: EPS of ($0.69) missed consensus (-$0.53) and revenue was $7.44M vs. $14.92M expected — the shortfall raises near-term execution and revenue questions. Earnings Release
• Negative Sentiment: Hedge fund BVF disclosed a large Q4 exit (sold ~2.56M PTGX shares, ~$170M), which can increase downward pressure on the stock and signal profit-taking by an institutional holder. Fool Coverage

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.